Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$10.05B-14.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bill Anderson
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 88,078
- Beta
- 0.83
- Country
- DE
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.08
Financials
Revenue
$10.05B-14.9%Net Income
$-672.00M-248.3%EBITDA
$1.52B-7.1%Free Cash Flow
$-89.00M-105.1%EPS (diluted)
$-0.17-241.7%Shares Outstanding (diluted)
3.93B+0.0%Operating Expenses
$5.45BCash & Debt
$12.60BReturn of Capital
$7.00MDividend per Share
$0.03Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $43.78B | $-3.48B | $-0.88 |
| 2024 | $46.61B | $-2.55B | $-0.65 |
| 2023 | $47.64B | $-2.94B | $-0.75 |
| 2022 | $50.74B | $4.15B | $1.06 |
| 2021 | $44.08B | $1.00B | $0.26 |
| 2020 | $41.40B | $-15.56B | $-3.96 |
| 2019 | $43.55B | $2.43B | $0.62 |
| 2018 | $39.59B | $1.70B | $0.45 |
| 2017 | $35.02B | $7.34B | $2.07 |
| 2016 | $46.77B | $4.53B | $1.36 |
| 2015 | $46.32B | $4.11B | $1.24 |
| 2014 | $42.24B | $3.43B | $1.03 |
| 2013 | $40.16B | $3.19B | $0.97 |
| 2012 | $39.76B | $2.45B | $0.73 |
Valuation
BAYRYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
55-28.26%Social Signal Score
Mentions (30)
- Newszacks.com·12d ago·Neutral
Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.
View source ↗ - Newsbusinesswire.com·13d ago·Negative
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) ha
View source ↗ - Newszacks.com·13d ago·Negative
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
View source ↗ - Newszacks.com·17d ago·Negative
BAYRY vs. JNJ: Which Stock Is the Better Value Option? Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsreuters.com·18d ago·Neutral
Bayer seeks bigger role in fast-growing Latin American biologicals market Bayer seeks bigger role in fast-growing Latin American biologicals market
View source ↗ - Newszacks.com·19d ago·Neutral
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well Bayer's Q3 earnings and revenues miss estimates, but strong growth in Nubeqa and Kerendia boosts pharma performance and lifts 2026 EBITDA guidance.
View source ↗ - Newsbusinesswire.com·19d ago·Negative
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEANI
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Bayer AG: Solid Q3 Earnings, But Still A 'Prove-It' Story Bayer A.G. maintains a 'Hold' rating after a robust Q3, with Pharma outperforming expectations and driving operating leverage. Q3 Pharma EBITDA before special items rose 23.6% to 1.292 billion euro, with margins improving to 27.6% from 24.1%. Core free cash flow guidance (ex-settlements) was upgraded to €3–4 billion, with settlement outflows peaking in 2026 and tapering thereafter.
View source ↗ - Newsseekingalpha.com·19d ago·Neutral
Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Negative
What Bayer Aktiengesellschaft (BAYN) Said on Its Q3 Earnings Call Bayer Aktiengesellschaft ETR: BAYN said it is on track to meet its 2026 commitments after reporting 3% organic sales growth and 7% adjusted EBITDA growth for the first nine months of the year, supported by Pharmaceuticals. The company raised its outlook for adjusted EBITDA, free cash flow and net financial debt, while maintaining its Core EPS guidance.
View source ↗ - Newswsj.com·19d ago·Negative
Bayer Raises Earnings Outlook on Pharma Recovery The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.
View source ↗ - Newsreuters.com·19d ago·Neutral
Bayer raises 2026 profit outlook Bayer raises 2026 profit outlook
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study,
View source ↗ - Newszacks.com·45d ago·Neutral
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
View source ↗ - Newsbusinesswire.com·45d ago·Negative
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background s
View source ↗ - Newszacks.com·46d ago·Positive
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Bayer Aktiengesellschaft (BAYRY) or Roche Holding AG (RHHBY). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newswsj.com·51d ago·Negative
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.
View source ↗ - Newsbusinesswire.com·51d ago·Positive
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer's long-term growth strategy and commitment to innovation and patient access in its l
View source ↗ - Newsreuters.com·54d ago·Negative
Bayer faces trial test of remaining Roundup claims after US Supreme Court win Attorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help determine the viability of some Roundup lawsuits after a US Supreme Court ruling in Bayer's favor this year.
View source ↗ - Newszacks.com·66d ago·Neutral
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
View source ↗ - Newsbusinesswire.com·66d ago·Negative
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adult
View source ↗ - Newsreuters.com·69d ago·Negative
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to resolve the litigation that has weighed on the German company for years.
View source ↗ - Newsreuters.com·72d ago·Negative
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkiller Roundup causes cancer.
View source ↗ - Newsbusinesswire.com·73d ago·Negative
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026
View source ↗ - Newszacks.com·73d ago·Neutral
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
View source ↗ - Newsbusinesswire.com·74d ago·Neutral
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
View source ↗ - Newsseekingalpha.com·81d ago·Neutral
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript
View source ↗ - Newsmarketbeat.com·81d ago·Negative
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s clean EBITDA margin and more than €3 billion in free operating cash flow by 2029.
View source ↗ - Newsreuters.com·81d ago·Neutral
Bayer says Crop Science unit makes progress on product launches Bayer said on Wednesday its Crop Science business had introduced two out of 10 planned new products with peak annual sales of at least €500 million ($579 million) each and mapped out further market launches.
View source ↗ - Newszacks.com·100d ago·Positive
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $0.17 per share
Typical surprise +23.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.09 vs $0.13miss
- Tue, Aug 4$0.29 vs $0.23beat
- Tue, May 12$0.79 vs $0.64beat
- Wed, Mar 4$0.18 vs $0.18beat
- Wed, Nov 12$0.17 vs $0.13beat
- Wed, Aug 6$0.35 vs $0.25beat
Estimates and results for BAYRY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed May 11, 2026 (33d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed May 11, 2026 (18d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed May 11, 2026 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 10, 2026 (24d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 14, 2025 (36d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 18, 2024 (29d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (47d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (22d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 22, 2024 (46d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 22, 2024 (46d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 20, 2024 (49d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 20, 2024 (49d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 20, 2024 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 20, 2024 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 20, 2024 (27d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 20, 2024 (27d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 22, 2024 (31d later)Buy$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 22, 2024 (31d later)Buy$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 10, 2023 (27d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 10, 2023 (26d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
